This half-day intellectual property summit, led by principals from Fish & Richardson’s life sciences practice, is designed for executives and in-house counsel in the pharmaceutical, biotechnology, and life sciences fields. Join us as we address critical issues at the forefront of these industries.
Space is limited, submit your registration request today.
Thought leaders will discuss the industry’s top challenges and provide insights and ideas your company can use to combat these challenges and avoid legal peril.
Learn about issues that will impact the future landscape of the life sciences industry. Fish & Richardson will apply for CLE credit in most states.
Network with colleagues from your field, and have one-on-one conversations with panelists after their presentations.
Registration & Networking
A View from the Bench
An interview with the Honorable Judge Leonard Davis, formerly of the Eastern District of Texas, conducted by Jonathan Singer, the head of Fish’s Life Sciences Practice.
Leonard Davis, Fish & Richardson
Jonathan Singer, Fish & Richardson
The Impact of Inter Partes Review (IPR) in Hatch-Waxman and Biologics Strategies
This presentation will explore the use of IPR from the standpoint of both generic and branded drug companies, including the interplay with Hatch-Waxman litigation and related timing issues. Speakers will also discuss the utility of this tool in the context of biosimilars development and freedom to operate.
Michael Kane, Fish & Richardson
Phil Nickson, Senior Patent Counsel, Momenta Pharmaceuticals, Inc.
Leslie Robbins, Coherus BioSciences
Dorothy P. Whelan, Fish & Richardson
Creative Enforcement, Management and Strategy throughout Multinational Patent Disputes
Pharmaceutical litigations have as global a reach as the drugs they concern. This session will address tips and tricks for coordinating litigation in civil law and commonwealth countries as well as creative domestic venues for possible enforcement. Discussion will cover major differences in law and procedure, ways to maximize differences in jurisdictions (such as timing, the fact finder, and scope and use of discovery), and both the benefits and potential pitfalls of having multiple law firms involved in multinational litigation.
Christian Chu, Fish & Richardson
Susan Coletti, Fish & Richardson
Mary Ellen Devlin, Executive Director, Boehringer Ingelheim USA Corporation
Elizabeth Flanagan, Fish & Richardson
Jonathan Singer, Fish & Richardson
Criminal and Regulatory Issues and Trends Facing Drug and Medical Device Industries: From GMP Violations to Anti-Corruption Enforcement
Panelists will touch on a number of recent criminal and regulatory issues facing drug and medical device companies including global anti-corruption efforts, off-label promotion, and Good Manufacturing Process (GMP) violations. The speakers will not only review important developments from the past year, but also forecast what to expect in 2016.
Gus P. Coldebella, Fish & Richardson
Thomas C. Frongillo, Fish & Richardson
William B. Mateja, Fish & Richardson
Peter M. Tran, GM and Senior Director, RSA
Speakers and hosts for the 2015 Life Sciences Summit, Cambridge, MA will be published as they are announced. To view full biographies for Fish & Richardson attorneys, please visit www.fr.com.
Conference materials will be posted as they become available. Download the Life Sciences IP Summit App, for Android and Apple devices, which will provide convenient access to materials during the event.
Take in spectacular views of the Charles River from one of the best hotels in the city. Freshly renovated with stylish updates and first-class amenities, the Royal Sonesta Boston couples modern design with chic comforts.
Royal Sonesta Boston
40 Edwin Land Boulevard
Cambridge, MA 02142
Please call the hotel directly to make reservations: 617-806-4200.
Fish & Richardson is a global patent, intellectual property (IP) litigation, and commercial litigation law firm with more than 400 attorneys and technology specialists across the U.S. and Europe. Fish has been named the #1 patent litigation firm in the U.S. for 11 consecutive years. Fish has been winning cases worth billions in controversy – often by making new law – for the most innovative clients and influential industry leaders since 1878. For more information, visit www.fr.com.
MIT’s Koch Institute for Integrative Cancer Research, a National Cancer Institute-designated Cancer Center, is a state-of-the-art cancer research facility as well as the hub of cancer research on the MIT campus. The Koch Institute brings together biologists and chemists along with biological, chemical, mechanical, and materials science engineers, computer scientists, clinicians and others, to bring fresh perspectives and an interdisciplinary approach to advancing the fight against cancer. This multi-faceted group of investigators is at the core of the Koch Institute’s mission to develop new insights into cancer, as well as new tools and technologies to better treat, diagnose and prevent the disease. For more information, visit ki.mit.edu.
Post-grant practice. Claims drafting. Patent litigation. Just a few examples of the specialized nature and depth of Suffolk Law’s IP concentration courses. The concentration offers students hands-on, skill-focused learning, combined with an innovative IP and Entrepreneurship Clinic whose students have successfully faced off against major brands. Our concentration is one of the largest and most developed of its kind in the country. It’s no surprise that in Boston’s largest IP firms, Suffolk Law has more patent law partners than any other law school in the country. For more information, visit www.suffolk.edu/law/.